Objective Studies investigating the association between BRCA2 Arg372His polymorphism and ovarian cancer risks have yielded conflicting results.
Methods We carried out a meta-analysis of 8488 ovarian cancer cases and 14,510 controls from 7 case-control studies in 5 articles published. The association between BRCA2 Arg372His polymorphism and ovarian cancer susceptibility was calculated using pooled odds ratios (ORs) appropriately derived from fixed effects models.
Results There were no significant associations between BRCA2 Arg372His polymorphisms and ovarian cancer risk in overall comparisons in all genetic models (HH vs NN: OR, 1.06; 95% confidence interval [95% CI], 0.96–1.18; P = 0.25; NH vs NN: OR, 1.02; 95% CI, 0.96–1.07; P = 0.6; NH + HH vs NN: OR, 1.01; 95% CI, 0.98–1.04; P = 0.42; HH vs NN + NH: OR, 1.06; 95% CI, 0.95–1.17; P = 0.29).
Conclusions This meta-analysis indicates that the BRCA2 Arg372His polymorphism is not associated with ovarian cancer risk for whites. Asian and African populations should be further studied.
- Ovarian cancer
- Gene polymorphism
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
This work was supported by the Natural Science Foundation of Shandong Province (ZR2014JL019), National High Technology Research and Development Program (“863” Program) of China (2014AA020605), China Postdoctoral Science Foundation (2014M551918), Science and Technology Development Project of Shandong Province (2014GSF118071, 2013GNC11306, 2013GSF12202), the National Natural Science Foundation of China (81272857), Independent Innovation Foundation of Shandong University (2012TS142).
The authors declare no conflicts of interest.